002020.SHE Zhejiang Jingxin Pharmaceutical Co Ltd
- Market cap
- CNY 10.1B
- P/E
- 13.1x
- P/B
- 1.61x
- ROE
- 11.7%
- Dividend yield
- 2.83%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002020.SHE undervalued?
Graham number002020.SHE trades 3.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Jingxin Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Jingxin Pharmaceutical Co Ltd yet.
Zhejiang Jingxin Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemirs, antidepressant, cephalosporin, and biopharma products; and API products, inc…
Full company profileZhejiang Jingxin Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Jingxin Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.88B | 2.22B | 2.94B | 3.65B | 3.26B | 3.47B | 3.78B | 4.00B | 4.16B | 4.07B | 4.05B |
| Gross Profit | 1.01B | 1.30B | 1.91B | 2.36B | 1.98B | 1.92B | 2.01B | 2.01B | 2.06B | 2.04B | 2.06B |
| Operating Income | 222M | 119M | 415M | 602M | 765M | 698M | 757M | 714M | 844M | 845M | 898M |
| EBITDA | 303M | 337M | 465M | 592M | 643M | 714M | 767M | 785M | 989M | 1.16B | 837M |
| Net Income | 200M | 264M | 369M | 520M | 653M | 613M | 662M | 619M | 712M | 758M | 703M |
| EPS | 0.26 | 0.33 | 0.43 | 0.64 | 0.83 | 0.75 | 0.77 | 0.72 | 0.83 | 0.88 | 0.82 |
| Balance Sheet | |||||||||||
| Total Assets | 3.29B | 4.90B | 4.99B | 5.63B | 5.67B | 6.42B | 7.36B | 7.99B | 8.48B | 8.12B | 8.12B |
| Total Liabilities | 864M | 938M | 1.42B | 1.91B | 1.73B | 1.58B | 2.19B | 2.45B | 2.48B | 2.25B | 2.07B |
| Shareholders' Equity | 2.38B | 3.92B | 3.56B | 3.70B | 3.92B | 4.82B | 5.15B | 5.51B | 5.97B | 5.83B | 6.01B |
| Cash & Short-term Investments | 262M | 334M | 411M | 2.44B | 2.09B | 1.98B | 1.92B | 1.61B | 1.14B | 531M | 336M |
| Total Debt | 200M | 186M | 150M | 359M | 301M | 168M | 296M | 310M | 304M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 253M | 385M | 523M | 535M | 513M | 365M | 856M | 825M | 726M | 781M | - |
| Capital Expenditure | 95.3M | 112M | 242M | 337M | 334M | 404M | 516M | 520M | 251M | 203M | 202M |
| Free Cash Flow | 157M | 273M | 281M | 198M | 179M | -39.4M | 340M | 273M | 476M | 578M | 821M |
| Ratios | |||||||||||
| ROE | 8.4% | 6.7% | 10.4% | 14.1% | 16.7% | 12.7% | 12.9% | 11.2% | 11.9% | 13.0% | 11.7% |
| ROA | 6.1% | 5.4% | 7.4% | 9.3% | 11.5% | 9.5% | 9.0% | 7.7% | 8.4% | 9.3% | 8.7% |
| Net Profit Margin | 10.7% | 11.9% | 12.5% | 14.3% | 20.0% | 17.7% | 17.5% | 15.5% | 17.1% | 18.6% | 17.4% |
| Debt to Equity | 0.08x | 0.05x | 0.04x | 0.10x | 0.08x | 0.03x | 0.06x | 0.06x | 0.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Jingxin Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.83%
- Forward dividend
- 0.35 CNY
- Payout ratio
- 37.6%
- Ex-dividend date
- Jun 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 285M | 0.33 | 37.6% |
| 2024 | CNY 258M | 0.30 | 36.3% |
| 2023 | CNY 258M | 0.30 | 41.7% |
| 2022 | CNY 258M | 0.30 | 39.0% |
| 2021 | CNY 231M | 0.28 | 37.8% |
| 2020 | CNY 232M | 0.29 | 35.5% |
| 2019 | CNY 206M | 0.25 | 39.6% |
| 2018 | CNY 143M | 0.16 | 38.7% |
| 2017 | CNY 64.0M | 0.08 | 24.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on May 28, 2021.
Who owns Zhejiang Jingxin Pharmaceutical Co Ltd
- Insiders 42.29%
- Institutions 7.94%
- Public & others 49.77%
- Shares outstanding 861M
- Free float 457M
Zhejiang Jingxin Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Jingxin Pharmaceutical Co Ltd
- Ticker
- 002020.SHE
- ISIN
- CNE000001K73
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 29, 2004
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,732
- Fiscal year end
- December
- Address
- No. 800, Xinchang Avenue East Road, Xinchang, China, 312500
- Phone
- 86 575 8617 6531
- Website
- jingxinpharm.com
About Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemirs, antidepressant, cephalosporin, and biopharma products; and API products, including ciprofloxacin, ciprofloxacin hydrochloride, ciprofloxacin lactate, levofloxacin hemihydrate, levofloxacin hydrochloride, levofloxacin lactate, enrofloxacin, enrofloxacin hydrochloride, simvastatin, rosuvastatin calcium, pitavastatin calcium, ticagrelor, rivaroxaban, apixaban, cisapride, levetiracetam, brivaracetam, sertraline HCI, rivastigmine bitartrate, pramipexole dihydrochloride, memantine hydrochloride, empagliflozin, dapagliflozin, marbofloxacin, and moxifloxacin. It also provides intermediates; and medical display products, such as diagnostic medical displays, endoscopy, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, medical imaging solutions, ultrasonic medical displays, and other products. The company was formerly known as Zhejiang Jingxin Pharmaceutical Factory and changed its name to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000. Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1990 and is headquartered in Xinchang, China.
Zhejiang Jingxin Pharmaceutical Co Ltd management
6- Mr. Lv GangPresident & Chairman of the Board · born 1962
- Ms. Chen MeiliVP & CFO · born 1970
- Mr. Yunfei HongSecretary of the Board & Non-Independent Director · born 1980
- Mr. Sheng LiuVice President · born 1976
- Ye Zhen ZhouAccounting Supervisor
- Mr. Jun Min WangVice President · born 1973